MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally.
Show moreShow less
The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Quality Score breakdown
Overall quality19/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability2
How much profit the company makes from its sales and capital
Quality Growth62
Are margins and returns getting better?
Cashflow2
Do the profits arrive as real cash?
Financial strength45
Debt, balance sheet and risk of trouble
Investment0
Does it invest with discipline instead of growing at any price?
Low Volatility69
How calm the share price moves, does not count
Price momentum25
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 3 officers or directors bought shares worth $142,690, most recently on Sep 1, 2026. Over the same period, 2 people sold shares worth $82,080. Buying cluster
SaleSamuel RubinsteinDirector525 shares at $12.72$6,678Sep 1, 2026
BuySamuel RubinsteinDirector2× since May 29, 2026: 675 shares, avg. $13.00$8,775Sep 1, 2026
BuyNachum ShamirDirector6,000 shares at $14.00$83,997Jun 3, 2026
BuyDavid Morton FoxDirector3,537 shares at $14.11$49,918Jun 1, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−16.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Start year 2020 (pandemic). Over 10 years: +39.7% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−40.6% (2020) → −149.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score19 · Bottom 25%
Profitability
Return on assets−27.7% · Below median
Net margin (12 months)−170.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−45.8% · Bottom 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
Mediwound Ltd has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Mediwound Ltd (MDWD)?
Mediwound Ltd reported trailing-twelve-month revenue of about $11.9M (latest available figure, as of Oct 31, 2026).
How solid is the balance sheet of Mediwound Ltd (MDWD)?
Balance-sheet figures for Mediwound Ltd (as of Oct 31, 2026): return on equity −72.4%, debt of 0.17 per unit of equity. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
Which stocks are comparable to Mediwound Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Mediwound Ltd (MDWD)?
The closing price on Nov 6, 2026 was $14.25. We carry closing prices from our data provider, not a live tick.
Key figures of Mediwound Ltd
How large is the market capitalisation of Mediwound Ltd (MDWD)?
The market capitalisation of Mediwound Ltd is $184M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mediwound Ltd (MDWD)?
The price-to-sales ratio of Mediwound Ltd is 14.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mediwound Ltd (MDWD)?
Earnings per share at Mediwound Ltd are $−2.17. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Mediwound Ltd (MDWD)?
The net margin of Mediwound Ltd is −141% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mediwound Ltd (MDWD)?
The return on equity (ROE) of Mediwound Ltd is −72.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mediwound Ltd (MDWD)?
On an EBIT basis the return on assets of Mediwound Ltd is −30.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mediwound Ltd (MDWD)?
The operating margin of Mediwound Ltd is −306% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mediwound Ltd (MDWD)?
Revenue at Mediwound Ltd is growing −45.8% versus a year earlier (3y avg −13.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Mediwound Ltd (MDWD) generate?
The free cash flow of Mediwound Ltd is −$20.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mediwound Ltd (MDWD) carry?
The net debt of Mediwound Ltd is $4.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mediwound Ltd in the live analysis
One click puts Mediwound Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Oct 31, 2026